Screener
4D Molecular Therapeutics FDMT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Issuance of common stock upon exercise of stock options | 1,674 | — |
| Issuance of common stock under the ATM offering program, net of issuance costs | 9,810 | — |
| Net cash provided by financing activities | 11,484 | — |
| Net increase (decrease) in cash and cash equivalents | 12,247 | (15,810) |
| Cash and cash equivalents, beginning of period | 60,241 | 149,336 |
| Cash and cash equivalents, end of period | $72,488 | $133,526 |
| Supplemental disclosures of noncash investing and financing information |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's financing cash flow?
- 4D Molecular Therapeutics (FDMT) reported financing cash flow of $11.48M in Q1 2026.
- What is the long-term trend for 4D Molecular Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's financing cash flow has grown at a -1.1% compound annual growth rate (CAGR), from $118.09M to $112.96M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about 4D Molecular Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude